CareDx International AB

DUBLIN, July 12, 2022 /PRNewswire/ -- The "Global Hospital Care Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. Global Hospital Care Partnering 2015 to 2022 provides the full collection of Hospital Care disease deals signed between the world's pharmaceutical and biotechnology companies since 2015. Trends in Hospital Care partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hospital Care partnering agreement structure Hospital Care partnering contract documents Top Hospital Care deals by value Most active Hospital Care dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Hospital Care disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hospital Care deals. The report presents financial deal terms values for Hospital Care deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Global Hospital Care Partnering 2015 to 2022 includes: Trends in Hospital Care dealmaking in the biopharma industry since 2015 Access to headline, upfront, milestone and royalty data Access to hundreds of Hospital Care deal contract documents Comprehensive access to over 1200 Hospital Care deal records The leading Hospital Care deals by value since 2015 Most active Hospital Care dealmakers since 2015 Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Hospital Care dealmaking 2.1. Introduction 2.2. Hospital Care partnering over the years 2.3. Hospital Care partnering by deal type 2.4. Hospital Care partnering by industry sector 2.5. Hospital Care partnering by stage of development 2.6. Hospital Care partnering by technology type 2.7. Hospital Care partnering by therapeutic indication Chapter 3 -Financial deal terms for Hospital Care partnering 3.1. Introduction 3.2. Disclosed financials terms for Hospital Care partnering 3.3. Hospital Care partnering headline values 3.4. Hospital Care deal upfront payments 3.5. Hospital Care deal milestone payments 3.6. Hospital Care royalty rates Chapter 4 - Leading Hospital Care deals and dealmakers 4.1. Introduction 4.2. Most active in Hospital Care partnering 4.3. List of most active dealmakers in Hospital Care 4.4. Top Hospital Care deals by value Chapter 5 - Hospital Care contract document directory 5.1. Introduction 5.2. Hospital Care partnering deals where contract document available Chapter 6 - Hospital Care dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by Hospital Care therapeutic target Companies Mentioned 3D-Side 3D Systems 3M 3SBio 4WEB Medical 7 Hills Pharma 7D Surgical 11 Health and Technologies 111 A&E Medical AAP Implantate AG Aatru Medical Abbvie Abiomed Ab Medica Abram Scientific Absolute Antibody AbSorber Acacia Pharma Acacia Research Acare Medical Science Accelus Accenture Access Scientific Accord Healthcare Accuray AccuTec Blades Acelity Acell Acelrx Pharmaceuticals Acentrus Specialty Acerus ActLight Acuity Healthcare Acuna-Fombona AdaptHealth Adaptimmune ADAS 3D Medical Adeor Medical Adhezion Biomedical ADIENNE Pharma & Biotech Admedus Advanced Aesthetic Technologies Advanced Cooling Therapy Advanced Guidance Technologies Advanced IT Concepts Advanced Ultrasound Systems Advantage Medical Advanz Pharma AdventHealth Aerapy Aerobiotix Aesculap Aesthetic Management Partners Aesthetic Medical International Aethlon Medical Aetna Agadia Systems AgeX Therapeutics Agiliti AgNovos Healthcare Aguettant Aidoc Aiforia Technologies AirStrip Technologies AirXpanders Aitrics Akari Therapeutics Akers Biosciences Akumin ALASTIN Skincare Alfasigma Algeos AliMed AliveCor ALK-Abello Allegheny Technologies Allenex Allergan Allergan Aesthetics Alliance Medical Allied Centre for Medical Excellence Alliqua Biomedical Alloksys Life Sciences AlloSource Almirall Alnylam Pharmaceuticals Alpha Imaging Alphamedix Alphatec Spine Altan Pharma Altaris Capital Partners Altasciences Altitude International Alume Biosciences Alvarado Hospital Medical Center Alyzen Medical Physics Amag Pharmaceuticals Ambra Health Ambu Amedica Amedisys Amendia Amend Surgical American Academy of Orthopaedic Surgeons American College of Chest Physicians American Health Imaging American Medical Technologies American Society for Aesthetic Plastic Surgery American Well Amerinet AmerisourceBergen Amgen AMI Amicrobe AMNIOX Amomed Pharma Amplifire Amplyx Pharmaceuticals Ancestry Anelixis Therapeutics Anelto Angiodynamics Angion Biomedica Angsana Molecular & Diagnostics Anika Therapeutics Anita Tecnica ANP Technologies Antares Pharma Anthem Antibe Therapeutics Apex Physics Partners ApiFix Apollo Endosurgery Appalachian Regional Healthcare Apple Applied DNA Sciences Applimotion APR Medtech Aptevo Therapeutics Archer Capital Arch Therapeutics argenx Argon Medical Devices Aridea Solutions Aridis Pharmaceuticals Arjo Arkansas Childrens Hospital Armaghan Salamat Kish Armis Biopharma Armor Arsenal Medical Artegraft Arteriocyte Medical Systems Arthrex Arthrosurface ARxIUM Asahi Kasei Ascendum Ascension Ascension Saint Thomas Asensus Surgical ASICO AskAt Asklepios Group Aspen Surgical Products Assure Astarte Medical Astellas Pharma AstraZeneca Asys Athersys Atlas Lift Tech ATL Technology Atnahs Pharma Atos Medical Atricure For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Allenex AB (STO:ALNX): For the fourth quarter, October - December · Net sales for the quarter were SEK 27.5 million (20.0), an increase of 37.5 percent year on year. The quarter’s results included full sales figures from Olerup GmbH, which was consolidated into the group as of June 1, 2011.

STOCKHOLM--(BUSINESS WIRE)-- Allenex (STO:ALNX.st - News) transfers its holdings in the portfolio companies NovaHep AB and Recopharma AB to Alden Impact Capital AG, Zurich, who takes responsibility for the continued financing of their activities. In NovaHep, focusing on liver stem cells, has Allenex been shareholder since 2005 and in Recopharma, with a focus on recombinant glyco proteins, since 2003. Allenex has been the sole financier of the companies' development work. Both companies have achieved valuable and promising results while there is still much work to be done before they can be commercialized. Allenex focus is now on the transplantation sector and in terms of liquidity the company prioritizes those activities. Agreement has now been reached with Alden Impact Capital AG, Zurich, a Swiss private equity manager linked to a family office, on the transfer of the holdings in NovaHep and Recopharma. The agreement includes a part of the future profits when Alden Impact Capital AG sells the holdings. Allenex will report a small loss in the second quarter of 2011 of SEK 280 thousand. A greater impairment of the holdings took place during the first quarter of 2011. "Today, it is extremely difficult to find financing of the development work carried out by NovaHep and Recopharma," says Anders Karlsson, CEO of Allenex. "It is therefore very satisfying that we by the transfer to Alden Impact Capital AG can ensure that both companies will be able to continue their operations." "NovaHep and Recopharma are two companies with a very exciting focus," says Stefan von Euw, Alden Impact Capital AG. "We will be able to financially support the continued development and so reach the next milestones." Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:10 (CET) on August 25, 2011 Allenex’s business focus is mainly on the transplantation business with subsidiary product companies AbSorber and Olerup SSP and the sales and distribution companies Olerup Inc. and Olerup GmbH. Allenex has also a portfolio of associated life science companies. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). For more information about Alden Impact Capital, please visit This information was brought to you by Cision Contact: Allenex ABAnders Karlsson, CEOtel: +4670-918 0010email: anders.karlsson@allenex.seorOkee Williamstel: +4670-60 053 64email: okee.williams@allenex.seorAlden Impact Capital AGStefan von Euwtel: +41 79 277 7581email: stefan@aldencapital.ch